UnitedHealth Group Incorporated (UNH) Stock Analysis 2026

HealthcareHealth Insurance & Health Services
$376.90
as of 2026-09-18
+9.0% (52-week)50D MA $411.74  |  200D MA $351.49

BriMind AI Score

Proprietary
52
Neutral
Price CAGR
12.2%
1Y Return
+7.5%
Analyst Upside
+25.4%
Rev Growth
0.4%

Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.

AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →

About UnitedHealth Group Incorporated

UnitedHealth Group is the largest healthcare company in the United States by revenue ($370B+) and the largest health insurer, covering 50+ million members. The company operates through two segments: UnitedHealthcare (insurance) and Optum (health services). Optum has become the more strategically important division, providing pharmacy benefit management (OptumRx), healthcare delivery (Optum Health with 90,000+ physicians), and data analytics (Optum Insight). UnitedHealth effectively controls a significant portion of the US healthcare value chain.

How UnitedHealth Makes Money

UnitedHealth earns from UnitedHealthcare (~60% of revenue — health insurance premiums from employer-sponsored, Medicare Advantage, and Medicaid plans) and Optum (~40% — pharmacy benefits, physician practices, surgical centers, and health data analytics). The insurance business earns from the medical loss ratio spread (premiums collected minus claims paid), while Optum earns fee-for-service and value-based care payments. The vertical integration between insurance and care delivery is the core competitive advantage.

UnitedHealth Revenue & Profitability Breakdown

This chart shows how UnitedHealth's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Revenue
$450.53B
Cost of Revenue
-$361.67B
Gross Profit
$88.86B19.7% margin
Operating Expenses
-$56.72B
Operating Income
$32.14B7.1% margin
Tax & Other
-$18.01B
Net Income
$14.12B3.1% margin
Gross Margin
19.7%
Operating Margin
7.1%
Net Margin
3.1%
EBITDA Margin
8.8%

Key Financial Metrics

UnitedHealth Group Incorporated trades at a trailing P/E of 25.51x, generates $24.27B in free cash flow, runs a debt/equity ratio of 69.21, and converts shareholder equity into profit at a 14.2% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Market Cap
$356.47B
Enterprise Value
$332.17B
P/E (Trailing)
25.51
P/E (Forward)
17.70
PEG Ratio
1.08
EV / EBITDA
9.17
Price / Sales
0.67
Price / Book
3.65
Revenue
$450.53B
Revenue Growth
0.4%
Earnings Growth
61.5%
EBITDA
$36.24B
EPS (Trailing)
$15.57
EPS (Forward)
$22.44
Gross Margin
19.7%
Operating Margin
7.1%
Net Margin
3.1%
Return on Equity
14.2%
Return on Assets
4.9%
Free Cash Flow
$24.27B
Total Cash
$34.29B
Total Debt
$81.27B
Debt / Equity
69.21
Current Ratio
0.78
Quick Ratio
0.69
Beta
0.62
Dividend Yield
2.3%
Payout Ratio
57.5%
Insider Ownership
0.2%
Inst. Ownership
89.8%
Short % Float
1.9%
Book Value / Share
$108.78

Wall Street Analyst Consensus

24 analysts covering UnitedHealth Group Incorporated currently lean toward a Buy rating, with a mean 12-month price target of $475.23 (+26.1% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

Consensus RatingBuy(24 analysts)
SellStrong Buy
Low Target$270.00-28.4%
Mean Target$475.23+26.1% upside
High Target$626.00+66.1%

Intrinsic Value Estimates for UNH

We use 4 valuation models to estimate UNH's intrinsic value. Intrinsic value is what a stock is truly worth based on the company's fundamentals, independent of what the market prices it at today. If multiple models agree the stock is undervalued, that convergence is a stronger signal.

Technical Price Signals

UNH is currently in a short-term downtrend, trading below its 50-day average of $411.74 and above its 200-day average of $351.49. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

Current Price
$376.90
50-Day MA
$411.74
▼ Price below
200-Day MA
$351.49
▲ Price above
Short-term Downtrend
Below 50-day MA — caution

UNH Investment Case: Bull vs Bear

UNH's investment case breaks down into 4 bull points and 4 bear points below. The bull case outlines the key reasons the stock could outperform — competitive advantages, growth catalysts, and market tailwinds. The bear case highlights the most significant risks. A strong bull case with manageable bear risks typically makes for a more compelling investment.

Bull Case (Reasons to Buy)

  • Vertical integration across insurance, pharmacy, and care delivery creates unmatched cost control and data advantages — UNH captures value at every step of the healthcare chain.
  • Medicare Advantage enrollment is growing as baby boomers age — UnitedHealthcare is the #1 MA plan with 30%+ market share.
  • Optum Health's 90,000+ physicians make it the largest employer of doctors in the US — shifting to value-based care improves margins and outcomes.
  • Consistent 13-16% annual EPS growth with a growing dividend — UNH has been one of the most reliable compounders in the S&P 500.

Bear Case (Key Risks)

  • Regulatory and political scrutiny is intensifying — the DOJ is investigating anticompetitive practices, and Congress is examining vertical integration in healthcare.
  • Medicare Advantage star ratings and reimbursement rate changes can significantly impact profitability in the government business.
  • Change Healthcare cyberattack (2024) exposed data of 100M+ people and cost $2B+ in remediation — cybersecurity remains an ongoing risk.
  • Valuation de-rating risk if regulatory concerns escalate — the stock's premium multiple depends on continued belief in the integrated model.

What to Watch: UNH Key Metrics

Medical loss ratio (medical care ratio)
Medicare Advantage enrollment growth
Optum Health revenue per consumer
EPS growth consistency
Regulatory and political developments

UNH Stock — Frequently Asked Questions

Read the full UNH in-depth report
Seven-method valuation, AI Score, blended price target, and a 5-year Monte Carlo simulation for UnitedHealth Group Incorporated.

Compare UNH with Peers

HCA vs UNHHCA Healthcare vs UnitedHealth Group — Hospital Operato
UNH vs CVSUnitedHealth vs CVS Health — Which Healthcare Giant Is
UNH vs ELVUnitedHealth vs Elevance — Which Health Insurer Is the
CI vs UNHCigna vs UnitedHealth — Health Insurer Comparison
CVS vs WBACVS Health vs Walgreens — Which Pharmacy Retailer Can S
MOH vs UNHMolina Healthcare vs UnitedHealth — Medicaid Specialist
UNH vs HUMUnitedHealth vs Humana — Diversified Health Giant vs Me
UNH vs CNCUnitedHealth vs Centene — Diversified Health Insurer vs

Unlock the Full UNH Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free TrialBrowse All Stocks
Data sources: Financial metrics and market data sourced from company SEC filings, earnings releases, and investor relations disclosures. Price data, analyst consensus targets, and fundamental financials provided by financial market data providers. ETF data sourced from official fund prospectuses and index provider publications. AI scores and price targets are proprietary estimates — see our Methodology and Disclaimer for details.
← Back to Home · Browse All Stock Analysis